You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Advances in

Innovative Treatment Paradigms in Diabetes Management

Second generation basal insulins have demonstrated clinical advantages over first-generation insulins, including less nocturnal hypoglycemia and greater dosing flexibility. Fixed-ratio combinations of basal insulin and GLP-1 RA provide effective glycemic control with a reduced hypoglycemia risk, mitigation of weight gain, and improved tolerability in T2DM. For T1DM, adjunctive non-insulin glucose-lowering agents may enable patients to achieve glycemic control with lower insulin doses, less hypoglycemia, glucose variability and weight gain. Education is needed to identify patients benefitting most from these novel therapies.

Insulin Innovation Fixed-Ratio Combinations Type 1 Diabetes

Supported by an independent educational grant from

Sanofi

Insulin Innovation and FRC programs developed through a partnership between Medscape and

Leicester Diabetes Centre

 

PCDE

Insulin Innovation

Fixed-Ratio Combinations

Steering Committee - Insulin Innovation & Fixed-Ratio Combinations

Francesc Xavier Cos Claramunt, MD

Francesc Xavier Cos Claramunt, MD

Associate Professor, Department of Medicine, Universitat Autonoma de Barcelona; Director, Saint Martí Primary Health Centres (Catalonian National Health Service); Chairman, Primary Care Diabetes Europe, Barcelona, Spain

Melanie J. Davies, CBE, MD

Melanie J. Davies, CBE, MD

Professor of Diabetes Medicine, Diabetes Research Unit, University of Leicester; Honorary Consultant Physician, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

Juan Pablo Frias, MD

Juan Pablo Frías, MD

Chief Executive Officer, Principal Investigator, National Research Institute, Los Angeles, California, United States

Stewart B. Harris, CM, MD, MPH

Stewart B. Harris, CM, MD, MPH

Professor, Department of Family Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, Ontario, Canada

Kamlesh Khunti, PhD, MD, FRCGP, FRCP

Kamlesh Khunti, PhD, MD, FRCGP, FRCP

Head of Department, Professor of Primary Care Diabetes and Vascular Medicine, Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, United Kingdom

Robert A. Ritzel, MD

Robert A. Ritzel, MD

Professor of Internal Medicine; Head, Division of Endocrinology and Diabetes, Städtisches Klinikum, Munich, Germany

New Horizons in Type 1 Diabetes Management

Supported by an independent educational grant from

Sanofi

Type 1 Diabetes

Steering Committee - Type 1 Diabetes

John B. Buse, MD, PhD

John B. Buse, MD, PhD

Verne S. Caviness Distinguished Professor; Chief, Division of Endocrinology; Director, North Carolina Translational and Clinical Sciences Institute; Executive Associate Dean, Clinical Research; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Thomas Danne, MD

Thomas Danne, MD

Professor, Hannover Medical School, Director, Children's Hospital AUF DER BULT, Hannover, Germany

Rory J. McCrimmon, MD, MBChB, FRCPE

Rory J. McCrimmon, MD, MBChB, FRCPE

Professor
University of Dundee
Dundee, United Kingdom

Polling Question

Related Resources

Downloadable Slide Kit

Innovative Treatment Paradigms in Diabetes Management: Insulin Innovation

Educational slides on the role of novel basal insulins in therapy for T2DM

Download

Innovative Treatment Paradigms in Diabetes Management: Insulin Combinations

Educational slides on the benefits of basal insulin/GLP-1 RA fixed ratio combinations

Download

Clinical Articles

Freemantle N, Chou E, Frois C, et al. Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open. 2016;6:e009421.  

Aroda V, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care. 2016;39:1972-1980.  

Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled with oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39:2026-2035.  

Lingvay I, Manghi FP, García-Hernández P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA. 2016;315:898-907  

Related Links

See All